Terns Pharmaceuticals, Inc. (TERN)

Over the past six months, Terns Pharmaceuticals' stock has increased significantly. The stock reached an all-time high closing price on December 11, 2025. Key events impacting the stock price include the discontinuation of TERN-601, equity inducement grants to new employees, presentation at the J.P. Morgan Healthcare Conference highlighting a strong cash position, and analyst coverage with a Market Perform recommendation.

As a clinical-stage biopharmaceutical company, Terns Pharmaceuticals does not have commercialized products generating revenue from sales. The company's financial performance is primarily driven by research and development milestones, clinical trial results, strategic partnerships, and financing activities rather than seasonal fluctuations in product demand.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics, operating within the Healthcare sector, specifically in the Biotechnology industry. Initially focused on liver diseases, the company strategically transformed into an oncology-focused entity by the end of 2025. Key product candidates include TERN-701, an oral BCR-ABL inhibitor for CML in Phase 1/2 clinical trials with Orphan Drug Designation; TERN-501, a THR-β agonist with positive Phase 2a data, previously developed for MASH; and TERN-801, a GIPR antagonist for obesity. TERN-601, an oral GLP-1 receptor agonist for obesity, was discontinued in October 2025.

Terns Pharmaceuticals is headquartered in Foster City, California, and maintains a significant operational footprint in Shanghai, China. Terns has licensed development and commercialization rights for TERN-701 in mainland China, Taiwan, Hong Kong, and Macau to Hansoh.

In the past year, Terns Pharmaceuticals' brand reputation has been shaped by its strategic pivot and pipeline progress. The company has garnered attention from analysts due to its promising drug candidates. Key events affecting its reputation include the strategic shift to oncology, the discontinuation of TERN-601, positive clinical data for TERN-701, and presence at industry conferences.

Terns Pharmaceuticals is predominantly owned by institutional investors. As of early February 2026, 255 institutional owners and shareholders held a total of 95,319,461 shares. Major institutional owners include Soleus Capital Management, L.P., Morgan Stanley, and Orbimed Advisors Llc, among others.